Sai Parenteral's Limited, a pharmaceutical formulations company, engages in the branded generic formulations and contract development and manufacturing businesses in India and internationally. Its portfolio includes formulation products across various therapeutic areas, such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology in various dosage forms, including injectables, tablets, capsules, liquid orals, and ointments. The company was founded in 1988 and is based in Hyderabad, India.
| Current Price | ₹456.00 |
|---|---|
| Market Cap | ₹2,153 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 110.9 |
| Return on Equity | 2.88% |
| 52-Week Range | ₹400.00 – ₹706.00 |
| Beta (1Y) | 0.44 |
| Revenue | ₹179 Cr |
|---|---|
| Net Profit | ₹8 Cr |
| EPS (Basic) | ₹1.79 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
1. Branded Generic Formulations-37% 2. CDMO Products and Services-63%
Sai Parenteral's Limited is trading at ₹456.00, with a market capitalisation of ₹2,153 Cr.
Sai Parenteral's Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Sai Parenteral's Limited has a P/E of 110.9 and a return on equity of 2.88%.
In Q1 FY27, Sai Parenteral's Limited reported revenue of ₹179 Cr and net profit of ₹8 Cr, with basic EPS of ₹1.79 (consolidated, parsed from the company's exchange filing).